Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 979,137 shares of the company's stock after acquiring an additional 112,847 shares during the quarter. Northern Trust Corp owned about 0.96% of Intellia Therapeutics worth $11,417,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ARK Investment Management LLC raised its holdings in Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after buying an additional 280,946 shares during the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after buying an additional 562,249 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $43,177,000. Geode Capital Management LLC boosted its position in shares of Intellia Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after purchasing an additional 45,930 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Intellia Therapeutics by 36.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock worth $23,042,000 after purchasing an additional 528,962 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NTLA. Guggenheim decreased their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Chardan Capital reiterated a "buy" rating and set a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Wall Street Zen upgraded shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.90.

Intellia Therapeutics Stock Up 2.8%

NASDAQ:NTLA traded up $0.26 on Thursday, reaching $9.46. 2,641,481 shares of the company's stock were exchanged, compared to its average volume of 2,558,724. The firm has a market capitalization of $979.90 million, a price-to-earnings ratio of -1.74 and a beta of 2.33. The business has a fifty day moving average of $7.98 and a 200-day moving average of $10.63. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. The firm's revenue for the quarter was down 42.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.12) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.